[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100144214":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":25,"locations":31,"responsibleParty":42,"collaborators":44,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":25,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":25,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":69,"whyStopped":25,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Boryung Pharmaceutical Co., Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"renal impairment patients","EXPERIMENTAL","renal impairment patients who eGFR is lower than 30 ml\u002Fmin\u002F1.73m\\^2 without hemodialysis",[13],"Drug: fimasartan",{"label":15,"type":16,"description":17,"interventionNames":18},"healthy volunteers","ACTIVE_COMPARATOR","healthy volunteers group",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","fimasartan","single administration of fimasartan 120mg",[15,9],null,[27],{"name":28,"affiliation":29,"role":30},"Yon Su Kim, PhD","Seoul National University College of Medicine","PRINCIPAL_INVESTIGATOR",[32],{"facility":33,"status":25,"city":34,"state":25,"zip":25,"country":35,"countryCode":25,"cosmosGeoPoint":36,"geoPoint":41,"contacts":25},"Seoul National University Hospital","Seoul","South Korea",{"type":37,"coordinates":38},"Point",[39,40],126.9784,37.566,{"lat":40,"lon":39},{"type":43,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[45],{"name":33,"class":46},"OTHER","100144214","phase-1-a-clinical-trial-to-compare-and-evaluate-the-pharmacokinetic-characteristics-and-the-safety-of-fimasartan-in-renal-impairment-patients-and-healthy-volunteers-100144214",false,"NCT01148368","A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Renal Impairment Patients and Healthy Volunteers","Inclusion Criteria:\n\n\\\u003CRenal impairment patient\\>\n\n* age: 20-65 years\n* eGFR: \\\u003C 30ml\u002Fmin\u002F1.73m\\^2\n* not on dialysis\n* body weight: greater than 55kg\n* written informed consent\n\n\\\u003CHealthy volunteer\\>\n\n* age: 20-65 years\n* body weight: greater than 55kg\n* written informed consent\n\nExclusion Criteria:\n\n* AST, ALT \\> 1.5 times of upper normal range\n* positive drug or alcohol screening",true,"ALL","20 Years","65 Years",{"count":58,"type":59},16,"ACTUAL","INTERVENTIONAL",[62],"PHASE1","The purpose of this study is to compare and evaluate the pharmacokinetic characteristics and the safety of fimasartan in renal impairment patients and healthy volunteers.",[65],"Renal Impairment",[22,67,68],"renal impairment","hypertension","COMPLETED","2012-01-06",{"date":72,"type":73},"2012-01-09","ESTIMATED",{"date":75,"type":25},"2010-06",{"date":77,"type":59},"2011-07",{"name":5,"class":6},1]